Whalesbook
Dr. Reddy's Laboratories reported its financial results for the fourth quarter and full fiscal year 2026. The company achieved Q4 FY26 revenue of ₹7,516 Cr, marking a 12% increase compared to the same period last year. For the full fiscal year 2026, revenue reached ₹33,593 Cr, up 3% year-over-year. In terms of profitability, the company reported Q4 FY26 profit after tax (PAT) of ₹220 Cr, and full-year FY26 PAT stood at ₹4,285 Cr.
Key Business Milestones:
The quarter saw significant progress on the product front. Dr. Reddy's secured approval in Canada for its generic semaglutide injection, a medication used for diabetes management. This was followed by the drug's launch in India under the brand name 'Obeda®'. The company also received approval from India's DCGI for its generic semaglutide tablets.
In its biologics segment, Dr. Reddy's submitted a Biologics Licence Application (BLA) to the US Food and Drug Administration (USFDA) for its proposed biosimilar to abatacept, intended for intravenous administration.
Further diversifying its portfolio, Dr. Reddy's acquired the established brands Progynova® and Cyclo-Progynova® from Bayer. This move integrates the company into the Hormone Replacement Therapy market.
Strategic Significance:
These developments are poised to drive future growth. The launch of generic semaglutide offers a more accessible treatment option in the expanding diabetes market. The USFDA submission for the abatacept biosimilar signifies advancement in the company's high-potential biologics pipeline.
The acquisition of Progynova and Cyclo-Progynova brands enhances Dr. Reddy's therapeutic breadth and strengthens its revenue streams, particularly in key European markets where these brands are well-established.
Background and Integration:
The acquisition of the hormone replacement therapy brands Progynova® and Cyclo-Progynova® from Bayer in Europe was completed in October 2023 for €1.1 billion. This strategic move significantly boosted Dr. Reddy's presence in this therapeutic area.
The company also continues to integrate its acquired nicotine replacement therapy (NRT) business from Famy Care Ltd., with 95% of the business by value integrated as of March 2026, pointing to successful asset consolidation. The BLA submission for the abatacept biosimilar was made to the USFDA in August 2023.
Future Outlook and Risks:
Investors will be tracking the market performance of the newly launched generic semaglutide in India and Canada. The progress and outcome of the USFDA's review for the abatacept biosimilar will also be closely watched. The financial contribution from the acquired Progynova and Cyclo-Progynova brands is expected to support overall performance.
Dr. Reddy's focus on biosimilars and complex generics signals a strategic move toward higher-value product segments. However, potential risks include fluctuations in general economic conditions and currency exchange rates in its operating markets, as well as increasing competition in both customer and supplier markets.
Peer Comparison:
Dr. Reddy's peers like Sun Pharmaceutical Industries and Zydus Lifesciences also reported robust growth in Q4 FY24, with revenue increases of 8% and 13% respectively. Cipla, while facing market pressures, also posted a 5% revenue growth. Like Dr. Reddy's, these companies are expanding globally and concentrating on niche areas such as specialty products and biosimilars to fuel future growth.